Suppr超能文献

先天性白内障手术后儿童青光眼行 Ahmed 青光眼阀植入术后的临床结果。

Clinical Outcomes After Ahmed Glaucoma Valve Implantation for Pediatric Glaucoma After Congenital Cataract Surgery.

机构信息

Department of Ophthalmology, Carmel Medical Center, Haifa, Israel.

出版信息

J Glaucoma. 2021 Jan 1;30(1):78-82. doi: 10.1097/IJG.0000000000001689.

Abstract

PRCIS

Ahmed valve success for glaucoma following congenital cataract surgery lasts at least 5 years in most eyes, and >10 years in some cases. The procedure is a valuable option for these patients.

PURPOSE

The aim of the study was to report on the results of Ahmed valve implantation in children with glaucoma following congenital cataract surgery.

PATIENTS AND METHODS

Medical records were reviewed for 41 pediatric eyes (27 patients) with glaucoma after congenital cataract surgery with Ahmed glaucoma valve (AGV) implantation between 2007 and 2018. The primary outcome measure was surgical success, defined as intraocular pressure (IOP) ≤22 mm Hg (with or without glaucoma medications) on 2 consecutive follow-up visits, without glaucoma reoperation, and without significant visual complications during the follow-up period.

RESULTS

Median age at the time of AGV implantation was 80 months (range: 14 to 146 mo) and the mean follow-up period was 61.1±46.5 months. The cumulative probability of surgical success was 95.1%, 89.8%, 83.1%, and 72.6% at 12, 24, 60, and 84 months, respectively. IOP significantly decreased from 35.8±7.4 mm Hg before valve implantation to 18.7±6.5 mm Hg at the last recorded visit (51.4% decrease; P<0.0001). Most eyes (79%) required medications for pressure control. Complications occurred in 14 eyes (34%), with 12 of these remaining successful. Early hypotony was the most common complication (19.5%). Retinal detachment occurred in 1 eye.

CONCLUSIONS

Despite a decrease in surgical success over time, AGV implantation was successfully used for IOP control in the majority of our pediatric eyes with glaucoma after congenital cataract surgery. Most complications were managed effectively and surgical success was maintained.

摘要

PRCIS

在大多数情况下,阿赫迈德阀(Ahmed valve)用于先天性白内障手术后青光眼的疗效至少持续 5 年,在某些情况下超过 10 年。该手术对这些患者而言是一种有价值的选择。

目的

本研究旨在报告阿赫迈德阀(AGV)植入治疗先天性白内障术后青光眼儿童的结果。

患者和方法

回顾了 2007 年至 2018 年间,41 只(27 例)儿童眼因先天性白内障术后青光眼行 AGV 植入术后的病历资料。主要观察指标为手术成功,定义为在 2 次连续随访中眼压(IOP)≤22mmHg(伴有或不伴有青光眼药物治疗),无需再次进行青光眼手术,且在随访期间无明显视觉并发症。

结果

AGV 植入时的中位年龄为 80 个月(范围:14 至 146 个月),平均随访时间为 61.1±46.5 个月。12、24、60 和 84 个月时的手术成功率分别为 95.1%、89.8%、83.1%和 72.6%。与植入前的 35.8±7.4mmHg 相比,眼压在最后一次随访时显著下降至 18.7±6.5mmHg(下降 51.4%;P<0.0001)。大多数(79%)眼需要药物控制眼压。14 只眼(34%)发生并发症,其中 12 只眼仍成功。早期低眼压是最常见的并发症(19.5%)。1 只眼发生视网膜脱离。

结论

尽管手术成功率随时间下降,但 AGV 植入术仍成功地用于控制大多数先天性白内障术后青光眼儿童的眼压。大多数并发症得到了有效处理,手术成功率得以维持。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验